Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma.

IF 3 Q3 IMMUNOLOGY

Antibodies Pub Date : 2025-03-18 DOI:10.3390/antib14010026

Wendy M Covert, Jane E Rogers

引用次数: 0

Abstract

Advanced gastric adenocarcinoma (GAC) carries a poor prognosis. Targeted therapy in GAC has traditionally been limited to anti-human epidermal growth factor receptor-2 and anti-vascular endothelial growth factor agents. Recent years have brought immune checkpoint therapy to the GAC treatment landscape. However, continued discovery of targeted therapy in GAC is needed. Claudins, transmembrane proteins located in tight junctions of epithelial and endothelial cells, help regulate cellular polarity. Claudin dysregulation has been linked to cancers and other diseases. Claudin 18.2 specifically has become a new novel and exciting biomarker for GAC. Many agents are in the investigative pipeline, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric T-cell therapy. Recently, zolbetuximab, an anti-claudin 18.2 monoclonal antibody, was the first of these agents to get FDA approval. Here, we review zolbetuximab's place in therapy along with other agents being explored.

查看原文本刊更多论文

晚期胃腺癌（GAC）预后不良。胃腺癌的靶向治疗传统上仅限于抗人表皮生长因子受体-2和抗血管内皮生长因子药物。近年来，免疫检查点疗法已进入 GAC 治疗领域。然而，GAC 的靶向治疗仍需继续探索。Claudin是位于上皮细胞和内皮细胞紧密连接处的跨膜蛋白，有助于调节细胞极性。Claudin失调与癌症和其他疾病有关。特别是 Claudin 18.2 已成为 GAC 的一种新的令人兴奋的生物标志物。许多药物正在研究中，包括单克隆抗体、抗体药物共轭物、双特异性抗体和嵌合 T 细胞疗法。最近，抗克劳丁 18.2 单克隆抗体唑贝妥昔单抗（zolbetuximab）成为这些药物中第一个获得 FDA 批准的药物。在此，我们将回顾唑贝妥昔单抗在治疗中的地位，以及正在探索的其他药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antibodies IMMUNOLOGY-

CiteScore

7.10

自引率

6.40%

发文量

审稿时长

11 weeks

期刊介绍： Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, immunoregulatory molecules.